The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

被引：0
|
作者：
Rachna T Shroff
Mark Yarchoan
Ashley O'Connor
Denise Gallagher
Marianna L Zahurak
Gary Rosner
Chimela Ohaji
Susan Sartorius-Mergenthaler
Vivek Subbiah
Ralph Zinner
Nilofer S Azad
机构：
[1] The University of Texas MD Anderson Cancer Center,
[2] Gastrointestinal Oncology,undefined
[3] Sidney Kimmel Comprehensive Cancer Center,undefined
[4] Johns Hopkins University,undefined
来源：
British Journal of Cancer | 2017年 / 116卷
关键词：
cholangiocarcinoma; trametinib; MEK; pazopanib; VEGF; RAS; angiogenesis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1402 / 1407
页数：5
相关论文
共 50 条
  • [31] A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
    Grilley-Olson, J. E.
    Bedard, P. L.
    Fasolo, A.
    Cornfeld, M.
    Cartee, L.
    Razak, A. R. Abdul
    Stayner, L. -A.
    Wu, Y.
    Greenwood, R.
    Singh, R.
    Lee, C. B.
    Bendell, J.
    Burris, H. A.
    Del Conte, G.
    Sessa, C.
    Infante, J. R.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (06) : 740 - 749
  • [32] Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
    Tanja Trarbach
    Beate Schultheis
    Thomas C. Gauler
    Vesile Schneider
    Dirk Strumberg
    Wilfried E. E. Eberhardt
    Stephanie Le Scouiller
    Marcelo Marotti
    Kathryn H. Brown
    Joachim Drevs
    Investigational New Drugs, 2012, 30 : 1962 - 1971
  • [33] Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
    Trarbach, Tanja
    Schultheis, Beate
    Gauler, Thomas C.
    Schneider, Vesile
    Strumberg, Dirk
    Eberhardt, Wilfried E. E.
    Le Scouiller, Stephanie
    Marotti, Marcelo
    Brown, Kathryn H.
    Drevs, Joachim
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (05) : 1962 - 1971
  • [34] A Comprehensive Literature Review on Efficient Synthetic Approaches and Polymorphism of Pazopanib (Votrient), a Tyrosine Kinase Inhibitor
    Chand, Onkar
    Chopra, Lalita
    Tiwari, Shashi Kant
    JOURNAL OF MOLECULAR AND ENGINEERING MATERIALS, 2024, 12 (03)
  • [35] Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
    Tullemans, Bibian M. E.
    Nagy, Magdolna
    Sabrkhany, Siamack
    Griffioen, Arjan W.
    Egbrink, Mirjam G. A. Oude
    Aarts, Maureen
    Heemskerk, Johan W. M.
    Kuijpers, Marijke J. E.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2018, 5
  • [36] Pazopanib-the Latest First-Line Standard of Care Targeted Kinase Inhibitor for the Treatment of Advanced Renal Cell Carcinoma
    Lu, Taylor Y.
    Rampersaud, Edward N.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2014, 6 : 25 - 32
  • [37] Inhibition of VEGF mediated post receptor signalling pathways by recently developed tyrosine kinase inhibitor in comparison with sunitinib
    Moravcik, Roman
    Stebelova, Katarina
    Bohac, Andrei
    Zeman, Michal
    GENERAL PHYSIOLOGY AND BIOPHYSICS, 2016, 35 (04) : 511 - 514
  • [38] A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
    J. E. Grilley-Olson
    P. L. Bedard
    A. Fasolo
    M. Cornfeld
    L. Cartee
    A. R. Abdul Razak
    L.-A. Stayner
    Y. Wu
    R. Greenwood
    R. Singh
    C. B. Lee
    J. Bendell
    H. A. Burris
    G. Del Conte
    C. Sessa
    J. R. Infante
    Investigational New Drugs, 2016, 34 : 740 - 749
  • [39] A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors
    Jazieh, Khalid
    Molina, Julian
    Allred, Jacob
    Yin, Jun
    Reid, Joel
    Goetz, Matthew
    Lim, Vun-Sin
    Kaufmann, Scott H.
    Adjei, Alex
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 307 - 314
  • [40] Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma
    Ranieri, Girolamo
    Mammi, Maria
    Di Paola, Eugenio Donato
    Russo, Emilio
    Gallelli, Luca
    Citraro, Rita
    Gadaleta, Cosmo Damiano
    Marech, Ilaria
    Ammendola, Michele
    De Sarro, Giovambattista
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 89 (02) : 322 - 329
12345